208 related articles for article (PubMed ID: 34672971)
1. CLIP-170S is a microtubule +TIP variant that confers resistance to taxanes by impairing drug-target engagement.
Thakkar PV; Kita K; Castillo UD; Galletti G; Madhukar N; Navarro EV; Barasoain I; Goodson HV; Sackett D; Díaz JF; Lu Y; RoyChoudhury A; Molina H; Elemento O; Shah MA; Giannakakou P
Dev Cell; 2021 Dec; 56(23):3264-3275.e7. PubMed ID: 34672971
[TBL] [Abstract][Full Text] [Related]
2. Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer.
Galletti G; Zhang C; Gjyrezi A; Cleveland K; Zhang J; Powell S; Thakkar PV; Betel D; Shah MA; Giannakakou P
Clin Cancer Res; 2020 Jul; 26(14):3771-3783. PubMed ID: 32321717
[TBL] [Abstract][Full Text] [Related]
3. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.
Mosca L; Ilari A; Fazi F; Assaraf YG; Colotti G
Drug Resist Updat; 2021 Jan; 54():100742. PubMed ID: 33429249
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a Covalent Microtubule Stabilizer in Taxane-Resistant Ovarian Cancer Models.
Yee SS; Risinger AL
Molecules; 2021 Jul; 26(13):. PubMed ID: 34279417
[TBL] [Abstract][Full Text] [Related]
5. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
[TBL] [Abstract][Full Text] [Related]
6. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
Gjyrezi A; Xie F; Voznesensky O; Khanna P; Calagua C; Bai Y; Kung J; Wu J; Corey E; Montgomery B; Mace S; Gianolio DA; Bubley GJ; Balk SP; Giannakakou P; Bhatt RS
J Clin Invest; 2020 Jun; 130(6):3287-3298. PubMed ID: 32478682
[TBL] [Abstract][Full Text] [Related]
7. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
Wang R; Wang H; Wang Z
J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
[TBL] [Abstract][Full Text] [Related]
8. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
9. Androgen receptor splice variants determine taxane sensitivity in prostate cancer.
Thadani-Mulero M; Portella L; Sun S; Sung M; Matov A; Vessella RL; Corey E; Nanus DM; Plymate SR; Giannakakou P
Cancer Res; 2014 Apr; 74(8):2270-2282. PubMed ID: 24556717
[TBL] [Abstract][Full Text] [Related]
10. Expression of GRP78 predicts taxane-based therapeutic resistance and recurrence of human gastric cancer.
Yang L; Yang S; Liu J; Wang X; Ji J; Cao Y; Lu K; Wang J; Gao Y
Exp Mol Pathol; 2014 Apr; 96(2):235-41. PubMed ID: 24602846
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.
Kenicer J; Spears M; Lyttle N; Taylor KJ; Liao L; Cunningham CA; Lambros M; MacKay A; Yao C; Reis-Filho J; Bartlett JM
BMC Cancer; 2014 Oct; 14():762. PubMed ID: 25312014
[TBL] [Abstract][Full Text] [Related]
12. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies to overcome taxane resistance in cancer.
Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
17. Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells.
Chang H; Rha SY; Jeung HC; Jung JJ; Kim TS; Kwon HJ; Kim BS; Chung HC
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1901-13. PubMed ID: 20217129
[TBL] [Abstract][Full Text] [Related]
18. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C
Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for tubulin recognition by cytoplasmic linker protein 170 and its autoinhibition.
Mishima M; Maesaki R; Kasa M; Watanabe T; Fukata M; Kaibuchi K; Hakoshima T
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10346-51. PubMed ID: 17563362
[TBL] [Abstract][Full Text] [Related]
20. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
